Innovations for Human Health
Business
Genova Biotech Co., Ltd. (Japan) is a wholly-owned subsidiary of Genova Inc. (hereinafter referred to as “Genova”), a research-driven global biopharmaceutical company with proprietary platform technologies.
Through its two proprietary platform technologies for engineering high-potency protein molecules and protein molecules with a prolonged blood half-life, Genova focuses on the invention, development and production of novel protein molecules with enhanced therapeutic potentials. Genova’s novel protein molecules have been patented in jurisdictions around the world including the United States, Japan, the European Union and China. Over the past 20 years, Genova has created and grown comprehensive research and production programs for laboratory-based innovation of novel genes and protein molecules, drug development, pilot production processes and commercial drug production, distribution and marketing.
Genova’s research and development efforts focus on innovating better protein drugs for the treatment of viral infections, cancer, and autoimmune diseases.
Products
Novaferon
Novaferon is a novel, non-naturally existing protein molecule that was invented with Genova’s proprietary technology for engineering high-potency protein molecules, using 12 human interferon cDNA sequences as gene templates.
The fragments of these DNA sequences were shuffled to systemically induce random mutations and connections of DNA fragments and to form a new gene library. The polypeptides encoded by the new gene library were screened to select the protein molecule with the best functional properties. A protein molecule with enhanced activities against viral infections and tumors and immunomodulating functions was selected and named Novaferon.
Nova-EPO／Nova-GM-CSF
Nova-EPO and Nova-GM-CSF are two patented novel molecules created by the fusion of either natural erythropoietin (EPO), or granulocyte-macrophage colony-stimulating factor (GM-CSF) polypeptide, respectively, with a novel mutated Fc fragment of human IgG, using Genova’s proprietary technology for engineering long-acting proteins. Nova-EPO and Nova-GM-CSF exhibit significantly longer stability that lead to a prolonged blood half-life. Both Nova-EPO and Nova-GM-CSF are being developed as the next generation of long-acting EPO and GM-CSF/G-CSF proteins.